Literature DB >> 24981059

Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure.

Chao Dai1, Hongyang Wang1, Sun-Sang J Sung1, Rahul Sharma1, Carol Kannapell1, Wei Han1, Qian Wang1, Anne Davidson2, Felicia Gaskin3, Shu Man Fu4.   

Abstract

Interferon alpha (IFNα) may play a significant role in systemic lupus erythematosus (SLE) pathogenesis. Recent literature suggests that IFNα does not correlate with disease activities and blockade of IFNα is not effective in treating SLE. This study aims to delineate further the role of IFNα in SLE. 12-week old NZM2328 and its congenic NZM2328.Lc1R27 (R27) female mice were challenged with adenovirus-IFNα (adeno-IFNα) or adenovirus-LacZ (adeno-LacZ). Only adeno-IFNα treated NZM2328 developed severe proteinuria and died of chronic glomerulonephritis (GN) and end stage renal disease. Adeno-IFNα treated R27 did develop immune complex-mediated GN but had normal renal function. Adeno-LacZ treated NZM2328 showed enlarged glomeruli and increased cellularity without immune complex deposition. Adeno-LacZ treated R27 did not show serological and histological abnormalities. Adeno-IFNα induced anti-dsDNA and anti-kidney autoantibodies in NZM2328 and R27. These results suggest that end organ damage is host-dependent and less related to autoimmunity and may have significant implications in SLE pathogenesis.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Interferon α; Mouse model for lupus nephritis; SLE

Mesh：

Substances：

Year:  2014        PMID： 24981059      PMCID： PMC4167638          DOI： 10.1016/j.clim.2014.06.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  15 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

2.  NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci.

Authors:  S T Waters; S M Fu; F Gaskin; U S Deshmukh; S S Sung; C C Kannapell; K S Tung; S B McEwen; M McDuffie
Journal:  Clin Immunol       Date:  2001-09       Impact factor: 3.969

3.  B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.

Authors:  Noam Jacob; Shunhua Guo; Alexis Mathian; Michael N Koss; Simona Gindea; Chaim Putterman; Chaim O Jacob; William Stohl
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

4.  Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner.

Authors:  Zheng Liu; Ramalingam Bethunaickan; Weiqing Huang; Umairullah Lodhi; Ingrid Solano; Michael P Madaio; Anne Davidson
Journal:  Arthritis Rheum       Date:  2011-01

5.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

6.  Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.

Authors:  M Petri; S Singh; H Tesfasyone; R Dedrick; K Fry; Pg Lal; G Williams; Jw Bauer; Pk Gregersen; Tw Behrens; Ec Baechler
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

7.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

Review 8.  Type I IFN system in the development and manifestations of SLE.

Authors:  Keith B Elkon; Alice Wiedeman
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

9.  Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.

Authors:  C Landolt-Marticorena; G Bonventi; A Lubovich; C Ferguson; T Unnithan; J Su; D D Gladman; M Urowitz; P R Fortin; J Wither
Journal:  Ann Rheum Dis       Date:  2008-09-04       Impact factor: 19.103

10.  Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis.

Authors:  Samuel T Waters; Marcia McDuffie; Harini Bagavant; Umesh S Deshmukh; Felicia Gaskin; Chao Jiang; Kenneth S K Tung; Shu Man Fu
Journal:  J Exp Med       Date:  2004-01-12       Impact factor: 14.307
View more
  15 in total

1.  TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.

Authors:  Sonya J Wolf; Jonathan Theros; Tammi J Reed; Jianhua Liu; Irina L Grigorova; Giovanny Martínez-Colón; Chaim O Jacob; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2018-06-08       Impact factor: 5.422

2.  IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

Authors:  Marta E Stremska; Chao Dai; Rajkumar Venkatadri; Hongyang Wang; Vikram Sabapathy; Gaurav Kumar; Sheethal Jose; Saleh Mohammad; Sun-Sang J Sung; Shu Man Fu; Rahul Sharma
Journal:  J Autoimmun       Date:  2019-05-15       Impact factor: 7.094

Review 3.  Pathogenesis of proliferative lupus nephritis from a historical and personal perspective.

Authors:  Shu Man Fu; Hongyang Wang; Chao Dai; Sun-Sang J Sung; Felicia Gaskin
Journal:  Clin Immunol       Date:  2016-08-31       Impact factor: 3.969

Review 4.  Targeting of type I interferon in systemic autoimmune diseases.

Authors:  Mary K Crow; Mikhail Olferiev; Kyriakos A Kirou
Journal:  Transl Res       Date:  2014-10-16       Impact factor: 7.012

Review 5.  Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Authors:  Antonios Psarras; Miriam Wittmann; Edward M Vital
Journal:  Nat Rev Rheumatol       Date:  2022-09-12       Impact factor: 32.286

6.  Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity.

Authors:  Zhenhuan Zhao; Bihua Xu; Shuang Wang; Mianjing Zhou; Yuefang Huang; Chaohuan Guo; Mengyuan Li; Jijun Zhao; Sun-Sang J Sung; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Ann Rheum Dis       Date:  2022-04-12       Impact factor: 27.973

7.  Epidermal injury promotes nephritis flare in lupus-prone mice.

Authors:  Kaitlyn L Clark; Tamra J Reed; Sonya J Wolf; Lori Lowe; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Autoimmun       Date:  2015-08-21       Impact factor: 7.094

8.  Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.

Authors:  Sara S McCoy; Tamra J Reed; Celine C Berthier; Pei-Suen Tsou; Jianhua Liu; Johann E Gudjonsson; Dinesh Khanna; J Michelle Kahlenberg
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

9.  Autoimmune experimental orchitis and chronic glomerulonephritis with end stage renal disease are controlled by Cgnz1 for susceptibility to end organ damage.

Authors:  Zhenhuan Zhao; Hui Qiao; Y Ge; C C Kannapel; Sun-Sang J Sung; Felicia Gaskin; Kenneth S K Tung; Shu Man Fu
Journal:  Clin Immunol       Date:  2021-01-19       Impact factor: 10.190

10.  High-throughput quantitative real-time RT-PCR assay for determining expression profiles of types I and III interferon subtypes.

Authors:  Lynnsey A Renn; Terence C Theisen; Maria B Navarro; Viraj P Mane; Lynnsie M Schramm; Kevin D Kirschman; Giulia Fabozzi; Philippa Hillyer; Montserrat Puig; Daniela Verthelyi; Ronald L Rabin
Journal:  J Vis Exp       Date:  2015-03-24       Impact factor: 1.355
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.